Therapeutic drug monitoring in patients with inflammatory bowel disease

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Thiopurine analogs and anti-tumor necrosis factor (TNF) agents have dramatically changed the therapeutics of inflammatory bowel diseases (IBD), improving short and long-term outcomes. Unfortunately some patients do not respond to therapy and others lose response over time. The pharmacokinetic properties of these drugs are complex, with high inter-patient variability. Thiopurine analogs are metabolized through a series of pathways, which vary according to the patients' pharmacogenetic profile. This profile largely determines the ratios of metabolites, which are in turn associated with likelihoods of clinical efficacy and/or toxicity. Understanding these mechanisms allows for manipulation of drug dose, aiming to reduce the development of toxicity while improving the efficacy of treatment. The efficacy of anti-TNF drugs is influenced by many pharmacodynamic variables. Several factors may alter drug clearance, including the concomitant use of immunomodulators (thiopurine analogs and methotrexate), systemic inflammation, the presence of anti-drug antibodies, and body mass. The treatment of IBD has evolved with the understanding of the pharmacologic profiles of immunomodulating and TNF-inhibiting medications, with good evidence for improvement in patient outcomes observed when measuring metabolic pathway indices. The role of routine measurement of metabolite/drug levels and antibodies warrants further prospective studies as we enter the era of personalized IBD care.

Original languageEnglish
Pages (from-to)3475-3484
Number of pages10
JournalWorld Journal of Gastroenterology
Volume20
Issue number13
DOIs
StatePublished - Apr 7 2014

Fingerprint

Drug Monitoring
Inflammatory Bowel Diseases
Pharmaceutical Preparations
Tumor Necrosis Factor-alpha
Pharmacogenetics
Immunologic Factors
Metabolic Networks and Pathways
Methotrexate
Anti-Idiotypic Antibodies
Therapeutics
Pharmacokinetics
Prospective Studies
Inflammation
Antibodies

Keywords

  • Adalimumab
  • Anti-tumor necrosis factor
  • Antibodies
  • Azathioprine
  • Drug level
  • Drug monitoring
  • Inflammatory bowel disease
  • Infliximab
  • Thioguanine
  • Thiopurines

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Therapeutic drug monitoring in patients with inflammatory bowel disease. / Yarur, Andres J.; Abreu, Maria T; Deshpande, Amar R; Kerman, David H; Sussman, Daniel A.

In: World Journal of Gastroenterology, Vol. 20, No. 13, 07.04.2014, p. 3475-3484.

Research output: Contribution to journalArticle

@article{d694d4c2afd84dacafef97476960f531,
title = "Therapeutic drug monitoring in patients with inflammatory bowel disease",
abstract = "Thiopurine analogs and anti-tumor necrosis factor (TNF) agents have dramatically changed the therapeutics of inflammatory bowel diseases (IBD), improving short and long-term outcomes. Unfortunately some patients do not respond to therapy and others lose response over time. The pharmacokinetic properties of these drugs are complex, with high inter-patient variability. Thiopurine analogs are metabolized through a series of pathways, which vary according to the patients' pharmacogenetic profile. This profile largely determines the ratios of metabolites, which are in turn associated with likelihoods of clinical efficacy and/or toxicity. Understanding these mechanisms allows for manipulation of drug dose, aiming to reduce the development of toxicity while improving the efficacy of treatment. The efficacy of anti-TNF drugs is influenced by many pharmacodynamic variables. Several factors may alter drug clearance, including the concomitant use of immunomodulators (thiopurine analogs and methotrexate), systemic inflammation, the presence of anti-drug antibodies, and body mass. The treatment of IBD has evolved with the understanding of the pharmacologic profiles of immunomodulating and TNF-inhibiting medications, with good evidence for improvement in patient outcomes observed when measuring metabolic pathway indices. The role of routine measurement of metabolite/drug levels and antibodies warrants further prospective studies as we enter the era of personalized IBD care.",
keywords = "Adalimumab, Anti-tumor necrosis factor, Antibodies, Azathioprine, Drug level, Drug monitoring, Inflammatory bowel disease, Infliximab, Thioguanine, Thiopurines",
author = "Yarur, {Andres J.} and Abreu, {Maria T} and Deshpande, {Amar R} and Kerman, {David H} and Sussman, {Daniel A}",
year = "2014",
month = "4",
day = "7",
doi = "10.3748/wjg.v20.i13.3475",
language = "English",
volume = "20",
pages = "3475--3484",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "13",

}

TY - JOUR

T1 - Therapeutic drug monitoring in patients with inflammatory bowel disease

AU - Yarur, Andres J.

AU - Abreu, Maria T

AU - Deshpande, Amar R

AU - Kerman, David H

AU - Sussman, Daniel A

PY - 2014/4/7

Y1 - 2014/4/7

N2 - Thiopurine analogs and anti-tumor necrosis factor (TNF) agents have dramatically changed the therapeutics of inflammatory bowel diseases (IBD), improving short and long-term outcomes. Unfortunately some patients do not respond to therapy and others lose response over time. The pharmacokinetic properties of these drugs are complex, with high inter-patient variability. Thiopurine analogs are metabolized through a series of pathways, which vary according to the patients' pharmacogenetic profile. This profile largely determines the ratios of metabolites, which are in turn associated with likelihoods of clinical efficacy and/or toxicity. Understanding these mechanisms allows for manipulation of drug dose, aiming to reduce the development of toxicity while improving the efficacy of treatment. The efficacy of anti-TNF drugs is influenced by many pharmacodynamic variables. Several factors may alter drug clearance, including the concomitant use of immunomodulators (thiopurine analogs and methotrexate), systemic inflammation, the presence of anti-drug antibodies, and body mass. The treatment of IBD has evolved with the understanding of the pharmacologic profiles of immunomodulating and TNF-inhibiting medications, with good evidence for improvement in patient outcomes observed when measuring metabolic pathway indices. The role of routine measurement of metabolite/drug levels and antibodies warrants further prospective studies as we enter the era of personalized IBD care.

AB - Thiopurine analogs and anti-tumor necrosis factor (TNF) agents have dramatically changed the therapeutics of inflammatory bowel diseases (IBD), improving short and long-term outcomes. Unfortunately some patients do not respond to therapy and others lose response over time. The pharmacokinetic properties of these drugs are complex, with high inter-patient variability. Thiopurine analogs are metabolized through a series of pathways, which vary according to the patients' pharmacogenetic profile. This profile largely determines the ratios of metabolites, which are in turn associated with likelihoods of clinical efficacy and/or toxicity. Understanding these mechanisms allows for manipulation of drug dose, aiming to reduce the development of toxicity while improving the efficacy of treatment. The efficacy of anti-TNF drugs is influenced by many pharmacodynamic variables. Several factors may alter drug clearance, including the concomitant use of immunomodulators (thiopurine analogs and methotrexate), systemic inflammation, the presence of anti-drug antibodies, and body mass. The treatment of IBD has evolved with the understanding of the pharmacologic profiles of immunomodulating and TNF-inhibiting medications, with good evidence for improvement in patient outcomes observed when measuring metabolic pathway indices. The role of routine measurement of metabolite/drug levels and antibodies warrants further prospective studies as we enter the era of personalized IBD care.

KW - Adalimumab

KW - Anti-tumor necrosis factor

KW - Antibodies

KW - Azathioprine

KW - Drug level

KW - Drug monitoring

KW - Inflammatory bowel disease

KW - Infliximab

KW - Thioguanine

KW - Thiopurines

UR - http://www.scopus.com/inward/record.url?scp=84897483249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897483249&partnerID=8YFLogxK

U2 - 10.3748/wjg.v20.i13.3475

DO - 10.3748/wjg.v20.i13.3475

M3 - Article

VL - 20

SP - 3475

EP - 3484

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 13

ER -